Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

NCT03775538 PHASE1, PHASE2 COMPLETED

This study is an extension to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety and tolerability of CDNF in patients with Parkinson's disease when dosed directly into the brain using an implanted investigational drug delivery system (DDS). Long-term safety of the DDS is also being evaluated. All patients will receive monthly infusions of either mid- or high-dose of CDNF for a period of 6 months.

Details

Lead sponsor	Herantis Pharma Plc.
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	15
Start date	Thu Jul 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Parkinson Disease
• Movement Disorders
• Neuro-Degenerative Disease
• Nervous System Diseases
• Brain Diseases

Interventions

• Cerebral Dopamine Neurotrophic Factor
• Renishaw Drug Delivery System

Countries

Sweden, Finland